Therapeutic Monoclonal Antibodies by James W. LarrickTherapeutic Monoclonal Antibodies by James W. Larrick

Therapeutic Monoclonal Antibodies

byJames W. Larrick, C. Borrebaeck

Paperback | January 1, 1990

Pricing and Purchase Info

$177.05 online 
$193.50 list price save 8%
Earn 885 plum® points

Prices and offers may vary in store

Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

A review of therapeutic antibodies which have commercial potential. It discusses PCR cloning of Igs, immortalization by gene transfer, scale up production, infectious diseases, viruses, bacteria, parisites, inflammation/immunology, blood grouping, cells, cytokines, tumours and MDR.
Title:Therapeutic Monoclonal AntibodiesFormat:PaperbackDimensions:369 pagesPublished:January 1, 1990Publisher:Palgrave MacmillanLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1349118966

ISBN - 13:9781349118960

Look for similar items by category:

Reviews

Table of Contents

The use of in vitro immunization, cloning of variable regions and scid mice for the production of human monoclonal antibodies; construction of recombinant therapeutic monoclonal antibodies; antibody-mediated cancer diagnosis and therapy; current status and future perspectives of chemoimmunoconjugates for the treatment of cancer; gangliosides as targets for monoclonal antibody therapy of cancer; mouse antibodies to carcinomas; therapeutic implication of monoclonal antibodies against multidrug resistant tumour cells; radioimmunotherapy with 90yttrium-anti-idiotype monoclonal antibody; immunoconjugates of a protein synthesis inhibiting drug; human monoclonal anti-idiotypic antibodies against a murine monoclonal antibody (Mab17-1A) as an anti-tumour vaccine; uses of human monoclonal antibodies to human cytomegalovirus and varicella-zoster virus; development of a human monoclonal antibody against cytomegalovirus with the aim of passive immunotherapy; characterization of human anti-cytomegalovirus monoclonal antibodies; immunoprotective capacities of human and murine monoclonal antibodies recognizing serotype specific and common determinants of gram-negative bacteria; pharmocokinetics of xomen TM-E5 in animals and humans; radomized placebo-controlled study of E5 monoclonal antiendotoxin antibody; human monoclonal antibodies against human red blood cells; CD7 monoclonal antibodies; large scale production of monoclonal antibodies; European regulatory issues.